Sign In
to Vote &
Create Storyboards.
 
Pfizer's recently released Q3 results were above street estimates, led by higher than expected sales of Prevnar. The company also raised its full year earnings guidance to $2.54 - $2.62 per share.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard